IMP-10250

CD19

Recombinant human CD19 His-tag protein (Glu21-Lys291) with 6×His tag at C-terminus was expressed in Chinese Hamster Ovary cell line.

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

CHO

Human

C-6×His

Glu21

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Predicted Molecular Mass: 31 kDa
SDS-PAGE: 50-65 kDa, under reducing conditions.

Glu21-Lys291

Measured by its binding ability in a functional ELISA. When Human CD19 Antibody (FMC63) is immobilized at 2.00 μg/mL (100 μL/well), Recombinant Human CD19 binds with an ED50 of 15.0-150 ng/mL.

<0.10 EU/μg of the protein by the LAL method.

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.

Reconstitute at 500 μg/mL in PBS.

Measured by its binding ability in a functional ELISA. When Human CD19 Antibody (FMC63) is immobilized at 2.00 μg/mL (100 μL/well), Recombinant Human CD19 binds with an ED50 of 15.0-150 ng/mL.